Results 101 to 110 of about 23,919 (200)
Infection and Drug ResistanceKetaki Niranjan Pathak, Shital Shrikant Ghogale Department of Microbiology, Symbiosis Medical College for Women (SMCW), Symbiosis International (Deemed University) (SIU), Pune, Maharashtra, IndiaCorrespondence: Ketaki Niranjan Pathak, Department of ...
Pathak KN, Ghogale SS
doaj
Infection and Drug Resistance, 2018 Michael Hogan,1 Mary Barna Bridgeman,1 Gee Hee Min,1 Deepali Dixit,1 Patrick J Bridgeman,1 Navaneeth Narayanan1,2 1Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; 2Division of ...
Hogan M +5 more
doaj
Frontiers in MicrobiologyBackgroundDue to the growing resistance to routinely used antibiotics, the search for new antibiotics or their combinations with effective inhibitors against multidrug-resistant microorganisms is ongoing.
Natalia Słabisz +6 more
doaj +1 more source
Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams [PDF]
, 2008 Cross-reactivity between aztreonam and penicillins is poor, but clinical tolerance of aztreonam has been assessed, by means of tolerance challenge tests, only in a few groups of penicillin-allergic patients.
Altomonte, Giorgia +6 more
core
Frontiers in PediatricsObjectiveTo evaluate efficacy and safety of ceftazidime-avibactam (CZA) in preterm infants with multidrug-resistant (MDR) or extensive drug-resistant (XDR) bacterial infections.MethodRetrospective analysis of clinical data was conducted on preterm ...
Shiqi Guang +6 more
doaj +1 more source
Clinical evaluation of aztreonam for complicated urinary tract infection [PDF]
, 1985 Aztreonamを複雑性尿路感染症に使用した.投与対象は1984年7月より1985年1月までの間に練馬総合病院泌尿器科, 立川共済病院泌尿器科に入院した複雑性尿路感染症15例である.Aztreonamは1回2 g 1日2回を静注または点滴静注で5日間連続投与した.U.T.I.薬効評価基準(第2版)に適合する11例の総合臨床効果は著効6例, 有効2例, 無効3例で有効例は全例単独感染, 無効例は全例混合感染症例であった.細菌学的効果ではグラム陰性菌はすべて除菌され ...
長久保, 一朗 +3 more
core
Indian pediatrics, 2006 Aztreonam belongs to the monobactam group of naturally occurring antibiotic compounds characterized by a monocycling ring structure. Aztreonam is the first monobactam that has been approved for use in pediatric medicine by US FDA in the year 1998.
Seema, Kapoor, Geeta, Gathwala
openaire +1 more source
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates [PDF]
The combination of aztreonam with ceftazidime/avibactam is considered a potential therapeutic approach for the treatment of infections caused by metallo-β-lactamase (MBL)-producing isolates.
Jian Xu +4 more
core +1 more source
Asian Journal of Medical SciencesBackground: Worldwide, the emergence of carbapenem-resistant enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global concern to public health as they are responsible for several serious infections that lead to elevated ...
Payel Chanda +3 more
doaj +1 more source